Neuropathic pain is a complex, chronic condition caused by damaged or dysfunctional somatosensory nervous system which results in severe, burning pain, tingling, numbness, and increased sensitivity to touch. Neuropathic pain treatments help in relieveing pain associated with neuropathy and neuropathic disorders such as diabetic neuropathy, postherpetic neuralgia, chemotherapy-induced neuropathy and spinal cord injury.
Market key trends:
The increasing prevalence of neuropathic disorders such as diabetes, postherpetic neuralgia and chemotherapy-induced peripheral neuropathy has boosted the growth of the U.S. neuropathic pain treatment market. It is estimated that over 100 million Americans suffer from chronic pain conditions out of which approximately 8 million suffer from neuropathic pain alone. Moreover, growing geriatric population is also fuelling the demand for neuropathic pain treatments as elderly people are more prone to develop neuropathic disorders. According to United Nations report, number of Americans aged 65 years or older is projected to increase from 46 million in 2018 to 94 million by 2060 which will further drive the market growth during the forecast period.
Segment Analysis
The U.S. neuropathic pain treatment market is dominated by drug class segment. Within the drug class segment, anticonvulsants sub-segment holds the largest share owing to the high adoption of drugs such as pregabalin and gabapentin for neuropathic pain management. These drugs are commonly prescribed due to their efficacy and availability of generic versions which make them affordable for patients.
Key Takeaways
The U.S. Neuropathic Pain Treatment Market Growth is expected to witness high over the forecast period of 2024 to 2031. Increasing incidence of neuropathic pain due to conditions like diabetes, chemotherapy induced neuropathy and trauma injuries are major factors fueling the market growth. The global U.S. Neuropathic Pain Treatment Market is estimated to be valued at US$ 2,492.96 million in 2024 and is expected to exhibit a CAGR of 3.8% over the forecast period 2024 to 2031.
Regional analysis:
The Western region holds the dominant share in the U.S. neuropathic pain treatment market. Factors such as high prevalence of neuropathic pain conditions like diabetes and cancer along with presence of advanced healthcare infrastructure and availability of reimbursement are contributing to the leading position of this region.
Key players:
Key players operating in the U.S. Neuropathic Pain Treatment market are Alpinestars S.p.A, LeMans Corporation, Dainese S.p.A, FOX, FLY Racing, GAERNE USA, TCX S.r.l., FLY Racing, Dr. Scholl's Shoes, and Kenneth Cole New York. Drugs manufactured by these players are prescribed frequently for the treatment of neuropathic pain in the U.S.
Explore more information on this topic, Please visit -
https://www.insightprobing.com/u-s-neuropathic-pain-treatment-market-share-and-demand-analysis/
Explore more trending article on this topic -
https://techaxen.com/medicine-testing-services-in-the-us-ensuring-product-safety-and-compliance/
Explore more trending article related this topic -
https://www.insightprobing.com/geotextile-market-share-and-demand-analysis/
Comments
0 comment